TY - JOUR
T1 - Platelet Transfusion in Cardiac Surgery Does Not Confer Increased Risk for Adverse Morbid Outcomes
AU - McGrath, Tory
AU - Koch, Colleen Gorman
AU - Xu, Meng
AU - Li, Liang
AU - Mihaljevic, Tomislav
AU - Figueroa, Priscilla
AU - Blackstone, Eugene H.
N1 - Funding Information:
All financial support was obtained within the Department of Cardiothoracic Anesthesia. There was no external source of funding for this project.
PY - 2008/8
Y1 - 2008/8
N2 - Background: Platelet transfusion has been reported to confer increased morbidity after cardiac surgery but prior studies were limited by confounding variables including red blood cell (RBC) transfusions. Our objective was to examine the impact of platelet transfusion on outcomes in cardiac surgery controlling perioperative risk factors. Methods: A total of 32,298 patients underwent on-pump isolated coronary artery bypass grafting (CABG), an isolated valve, or a combined CABG and valve procedure between January 1, 1993 and January 1, 2006. Regression analysis and propensity methodology was employed to assess the association between platelet transfusion and morbidity. Results: Univariate comparisons demonstrated that patients who received platelet transfusions had increased morbidity. After risk adjustment with both multivariable regression and propensity methods, platelet transfusion was not significantly associated with in-hospital mortality: odds ratio (OR) 0.74 confidence limits 0.58, 0.95, p = 0.017 and 2.05% vs 3.06%, p = 0.017, respectively. Among 2,774 propensity matched-pairs, platelet transfusion was associated with similar or reduced morbidity, platelets versus no platelets: cardiac 2.42% vs 1.77%, p = 0.09; pulmonary 8.94% vs 9.88%, p = 0.23; renal 1.33% vs 1.48%, p = 0.65; neurologic 2.27% vs 3.21%, p = 0.033; serious infection 4.15% vs 5.34%, p = 0.037; and composite outcome 15.0% vs 17.2%, p = 0.024. Among a propensity-matched subgroup of patients never administered a concomitant RBC transfusion, platelet transfusion was not associated with increased morbidity: 4.49% vs 2.99%, p = 0.31. Conclusions: Platelet transfusion was not found to increase morbid risk after cardiac surgery. Our results should not be interpreted as advocating platelet transfusions in cardiac surgery; rather, platelet transfusion empirically in the setting of persistent microvascular bleeding is not associated with increased morbid risk.
AB - Background: Platelet transfusion has been reported to confer increased morbidity after cardiac surgery but prior studies were limited by confounding variables including red blood cell (RBC) transfusions. Our objective was to examine the impact of platelet transfusion on outcomes in cardiac surgery controlling perioperative risk factors. Methods: A total of 32,298 patients underwent on-pump isolated coronary artery bypass grafting (CABG), an isolated valve, or a combined CABG and valve procedure between January 1, 1993 and January 1, 2006. Regression analysis and propensity methodology was employed to assess the association between platelet transfusion and morbidity. Results: Univariate comparisons demonstrated that patients who received platelet transfusions had increased morbidity. After risk adjustment with both multivariable regression and propensity methods, platelet transfusion was not significantly associated with in-hospital mortality: odds ratio (OR) 0.74 confidence limits 0.58, 0.95, p = 0.017 and 2.05% vs 3.06%, p = 0.017, respectively. Among 2,774 propensity matched-pairs, platelet transfusion was associated with similar or reduced morbidity, platelets versus no platelets: cardiac 2.42% vs 1.77%, p = 0.09; pulmonary 8.94% vs 9.88%, p = 0.23; renal 1.33% vs 1.48%, p = 0.65; neurologic 2.27% vs 3.21%, p = 0.033; serious infection 4.15% vs 5.34%, p = 0.037; and composite outcome 15.0% vs 17.2%, p = 0.024. Among a propensity-matched subgroup of patients never administered a concomitant RBC transfusion, platelet transfusion was not associated with increased morbidity: 4.49% vs 2.99%, p = 0.31. Conclusions: Platelet transfusion was not found to increase morbid risk after cardiac surgery. Our results should not be interpreted as advocating platelet transfusions in cardiac surgery; rather, platelet transfusion empirically in the setting of persistent microvascular bleeding is not associated with increased morbid risk.
UR - http://www.scopus.com/inward/record.url?scp=47149109677&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=47149109677&partnerID=8YFLogxK
U2 - 10.1016/j.athoracsur.2008.04.051
DO - 10.1016/j.athoracsur.2008.04.051
M3 - Article
C2 - 18640332
AN - SCOPUS:47149109677
SN - 0003-4975
VL - 86
SP - 543
EP - 553
JO - Annals of Thoracic Surgery
JF - Annals of Thoracic Surgery
IS - 2
ER -